BCL2L1 and nonpapillary renal cell carcinoma: Finally, an orally bioavailable BCL-XL inhibitor, A-1331852, showed antitumor efficacy in vivo.<h4>Conclusions</h4>Our studies uncovered an unexpected link between cell state and BCL-XL dependence in ccRCC.